8-K: Global Medical REIT Prices 8.00% Series B Preferred Stock Offering

Global Medical REIT Inc. announced the pricing of an underwritten public offering of 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock at $25.00 per share.

Summary

• Global Medical REIT Inc. (the "Company") entered into an Underwriting Agreement for the issuance and sale of 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock, par value $0.001 per share.
• The public offering price is $25.00 per share, resulting in a total public offering value of $50,000,000 for the firm shares, before underwriting discounts.
• The Company granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of Series B Preferred Stock to cover over-allotments.
• The Series B Preferred Stock will pay cumulative cash dividends at an annual rate of 8.00% ($2.00 per share), payable quarterly in arrears on January 31, April 30, July 31, and October 31, commencing January 31, 2026.
• The offering is expected to close on November 20, 2025, subject to customary closing conditions.
• The Company intends to contribute the net proceeds from the sale of the Series B Preferred Stock to Global Medical REIT L.P., its operating partnership, in exchange for an equivalent number of 8.00% Series B Cumulative Redeemable Preferred Units.
• The Series B Preferred Stock has no stated maturity and is redeemable by the Company, at its option, on or after November 20, 2030, at a redemption price of $25.00 per share plus accrued and unpaid dividends.
• Upon a Change of Control, the Company has a special optional redemption right, and holders have a conversion right into Common Stock, subject to a Share Cap of 1.55666 shares of Common Stock per preferred share.
• The Company filed Articles Supplementary with the Maryland State Department of Assessments and Taxation on November 18, 2025, to designate 2,300,000 shares of its authorized preferred stock as Series B Preferred Stock, effective upon filing.

Sentiment

Score: 6

Explanation: The filing describes a successful capital raise, which is generally positive for a company's financial flexibility. However, the 8.00% fixed dividend represents a significant cost of capital, and the ultimate impact depends on the effective deployment of these funds, which is not detailed in this specific filing. It's a routine financing event for a REIT.

Positives

• The successful pricing of the preferred stock offering provides Global Medical REIT with additional capital, enhancing its financial flexibility.
• The 8.00% cumulative dividend rate offers an attractive fixed income stream for preferred shareholders.
• The perpetual nature of the Series B Preferred Stock (unless redeemed) provides long-term capital without a mandatory repayment date for the Company.
• The Company's intention to list the Series B Preferred Stock on the NYSE under GMRE-PrB is expected to provide liquidity for investors.

Negatives

• The 8.00% fixed dividend rate represents a significant ongoing cost of capital for the Company, which must be paid before common stock dividends.
• Restrictions are placed on the Company's ability to make distributions or payments on junior or parity capital stock if dividends on the Series B Preferred Stock are not declared and paid.
• The conversion right for preferred shareholders upon a Change of Control is subject to a Share Cap, which may limit the upside for preferred holders if the common stock price significantly increases.

Risks

• The Company's ability to make distributions or payments on capital stock ranking junior to or on parity with the Series B Preferred Stock will be restricted if distributions on the Series B Preferred Stock are not declared during any distribution period.
• If six or more quarterly dividends on the Series B Preferred Stock are in arrears, holders of Series B Preferred Stock (and other Voting Preferred Stock) gain the right to elect two additional directors to the Board, potentially impacting corporate governance.
• Supermajority approval (two-thirds of voting preferred stock) is required for certain actions, such as authorizing or issuing any class or series of Senior Equity Securities, or materially and adversely affecting the rights of Series B Preferred Stock holders, which could limit the Company's future financing flexibility.
• The Series B Preferred Stock is subject to restrictions on Beneficial Ownership and Constructive Ownership and Transfer as defined in the Company's Charter, which may affect certain investors' ability to hold or transfer shares.

Future Outlook

The Company intends to continue to meet the requirements for qualification and taxation as a Real Estate Investment Trust (REIT) under the Code for its taxable year ending December 31, 2025, and thereafter, unless its Board of Directors determines it is no longer in the Company's best interests. The Company will use its best efforts to list the Series B Preferred Stock on the NYSE within 30 days after the First Closing Date and maintain such listing.

Management Comments

• Jamie A. Barber, Secretary and General Counsel, signed the Form 8-K and the Underwriting Agreement on behalf of Global Medical REIT Inc. and Global Medical REIT L.P.
• Mark O. Decker, Jr., Chief Executive Officer and President, signed the Articles Supplementary on behalf of Global Medical REIT Inc.

Industry Context

This preferred stock offering by Global Medical REIT Inc., a healthcare REIT, aligns with a common strategy in the REIT sector to raise capital for acquisitions, debt repayment, or general corporate purposes. Preferred stock provides a stable, fixed-income component to the capital structure, often appealing to income-focused investors. The 8.00% dividend rate reflects current market conditions and the Company's credit profile within the medical office and healthcare real estate industry. Many REITs utilize preferred equity to diversify their funding sources and maintain lower leverage on their common equity.

Comparison to Industry Standards

• The 8.00% dividend rate for cumulative redeemable preferred stock is competitive within the REIT sector, particularly for healthcare REITs, reflecting a balance between investor yield expectations and the company's cost of capital. For example, other healthcare REITs or similar income-generating real estate companies might issue preferred stock with dividend rates ranging from 6.5% to 8.5% depending on market conditions, credit ratings, and specific terms.
• The $25.00 liquidation preference per share is a standard par value for preferred stock offerings in the U.S. market, making it comparable to preferred shares issued by peers like Omega Healthcare Investors (OHI) or Physicians Realty Trust (DOC) which also utilize preferred equity in their capital structures.
• The perpetual nature of the Series B Preferred Stock, coupled with a call option after five years (November 20, 2030), is a common structure for preferred equity, offering the issuer flexibility to refinance at potentially lower rates in the future while providing long-term income for investors. This is consistent with preferred stock terms seen from companies such as Public Storage (PSA) or Realty Income (O).
• The inclusion of conversion rights upon a Change of Control and specific voting rights for preferred shareholders in the event of dividend arrears are standard corporate governance provisions designed to protect preferred investors, similar to those found in preferred stock issuances across various industries, including other REITs.

Corporate Governance

Stakeholder Impact

• **Shareholders (Common Stock)**: Potential dilution of voting power in specific scenarios (e.g., dividend arrears leading to preferred director election). Fixed dividend payments to preferred shareholders will take precedence over common dividends, potentially impacting future common dividend capacity.
• **Preferred Shareholders (Series B)**: Receive a stable, cumulative 8.00% annual dividend. Have liquidation preference and specific voting rights for protection. Benefit from potential listing on NYSE for liquidity.
• **Operating Partnership**: Receives net proceeds from the offering in exchange for Series B Preferred Units, which can be used for its strategic objectives (e.g., acquisitions, debt reduction).
• **Underwriters**: Earn underwriting discounts and commissions for facilitating the offering.

Next Steps

• The Offering is expected to close on November 20, 2025, subject to customary closing conditions.
• The Company will contribute the net proceeds from the sale of Series B Preferred Stock to the Operating Partnership in exchange for Series B Preferred Units.
• The Company intends to file an application to list the Series B Preferred Stock on the NYSE under the symbol GMRE-PrB and expects trading to begin within 30 days after issuance.
• The Company will continue to use its best efforts to qualify and be taxed as a REIT for its taxable year ending December 31, 2025, and thereafter.

Key Dates

Recommendation

This filing primarily concerns a financing event, specifically a preferred stock offering, rather than operational performance. While the capital raise provides financial flexibility, the 8.00% fixed dividend represents a significant cost of capital. The ultimate impact on common equity value depends on the Company's ability to deploy these funds to generate returns exceeding this cost. Without specific details on the use of proceeds for new investments or debt reduction, and given it's a routine capital structure adjustment for a REIT, a 'hold' recommendation is appropriate for existing common shareholders. Income-focused investors might find the preferred stock attractive, but this recommendation is for the common stock based on the filing's content.

Keywords

Global Medical REIT, Preferred Stock, Series B Preferred Stock, Capital Raise, Underwriting Agreement, Dividend, REIT, Healthcare Real Estate, Equity Offering, Corporate Finance, NYSE, GMRE